One Year Later: A Bold Step Forward for Medical Communications

Real Chemistry is known for its 20-year history of staying ahead of client needs, driving innovation throughout healthcare communications, and empowering our people. A year ago, we took a bold step by creating a dedicated medical capabilities business unit and acquiring Avant Healthcare to deepen our impact in medical communications. Today, I’m proud to share how we’ve evolved—not just by uniting our expertise under the unified team of Real Chemistry Medical Communications but by listening, adapting and investing in the future of healthcare provider scientific engagement. 

Since our teams came together to build one of the largest medical communications expertise practices in the industry, we’ve accomplished the following milestones:  

1. Established industry leading end-to-end medical expertise in oncology, neurology, cardiovascular/metabolic and immunology 

2. Developed best in class precision medicine/diagnostic partnerships 

3. Expanded our biotech and scientific visualization business 

Client Feedback Drives Our Innovation 

The gap between scientific discovery and real-world patient care continues to grow. Healthcare providers are navigating an overwhelming volume of data while balancing the demands of patient care, making the need for clear, actionable medical communications more critical than ever. 

At Real Chemistry, we are tackling this challenge head-on. Our Medical Communications team is helping biopharma translate groundbreaking science into real impact—ensuring that life-changing innovations don’t remain static text in journals but dynamically reach the providers and patients who need them most. 

To do this effectively, we’ve engaged in ongoing conversations with clients, industry leaders and our own experts, refining our approach to meet today’s challenges and anticipate tomorrow’s needs. Our focus remains on delivering precise, clear and impactful engagement strategies that help healthcare providers make informed decisions and improve patient outcomes; and with that comes key investments we are making at Real Chemistry.  

Investing in the Tools That Translate to Impact  

To make this happen, we’re investing in AI-enabled solutions with deep scientific expertise, building a powerful suite of tools and strategies to support our clients in breaking through the noise. Our focus is clear: helping biotech and pharma engage healthcare providers with precision, clarity and urgency.  

We’ve identified three critical areas where we are dedicating resources, talent and innovation to ensure medical breakthroughs don’t get lost in complexity but lead to meaningful patient outcomes:  

• AI-Enabled Publication Tools: As we move into Phase II of development, our enhanced AI-powered approach will transform the delivery of clinical data to healthcare providers. By streamlining literature reviews, data extraction, and manuscript development, we accelerate scientific dissemination while maintaining strict data privacy.  

• Biotech-Focused Solutions: With breakthroughs in cell and gene therapy, mRNA, and CRISPR, we’re empowering biotech companies to effectively communicate their clinical advancements. Our tailored strategies help engage key audiences, drive research momentum, and support regulatory success—especially in high-need areas like rare diseases.  

• Precision Medicine/Diagnostics Expertise: We have launched a dedicated team to refine targeted treatment strategies. Using AI-driven genetic and biomarker analysis, we help clients deliver impactful, personalized messaging that ensures patients receive the right therapies at the right time. 

Strengthening Our Leadership & Vision 

With this transformation, we’ve expanded our leadership team, bringing together some of the brightest minds in medical communications: 

• Kathleen Barrett, MBA, Global Chief Operating Officer

• Sarah Black, EVP, US Promotional Medical Education

• Oli Burnham, President, Global Medical Communications

• Erin Crocker, Head of US Medical Affairs

• Jason Gardner, Ph.D., SVP, Global Head of Medical

• Jesse Johanson, MS, EVP, Head of Business Strategy

• Patrick Kelley, MBA, Global Chief Creative Officer

• Celine Parmentier, Ph.D., SVP, Global Medical Education

• Brandon Pletsch, MS, President, Scientific Visualization

• Ujwal “Uj” Pyati, Ph.D., Chief Medical Officer

• Audrey Schnelker, PMP, Head of Project Management

• Sarah Wilson, Ph.D, SVP, US Medical

• Todd Wright, MBA, Chief Commercial Officer

Each leader brings expertise that reinforces our commitment to innovation, creativity, and scientific excellence. 

Charting Our Path Forward  

The launch of the Real Chemistry Medical Communications website marks a pivotal step in our evolution. This platform highlights our expertise, industry leadership, and commitment to transforming medical communications. It’s designed as a resource for our biopharma partners, showcasing how we integrate scientific strategy, technology, and data-driven insights to enhance HCP engagement and, ultimately, patient care.  

In today’s fast-changing healthcare landscape, clear, science-driven communication has never been more critical. With rapid clinical advancements, evolving regulations, and increasing provider burnout, biopharma must engage HCPs effectively to ensure breakthrough therapies reach the right patients at the right time. 

Connect with us today to discover how we can elevate your healthcare communications and build stronger connections with HCPs.